How to buy GW Pharmaceuticals shares | $100.44
Own GW Pharmaceuticals shares in just a few minutes.
GW Pharmaceuticals plc is a drug manufacturers—general business with stocks listed in the US. GW Pharmaceuticals shares (GWPH) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$100.44 – an increase of 0.38% over the previous week.
How to buy shares in GW Pharmaceuticals
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for GW Pharmaceuticals. Find the share by name or ticker symbol: GWPH. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until GW Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$100.44, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of GW Pharmaceuticals, depending on your broker.
- Check in on your investment. Congratulations, you own a part of GW Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- GW Pharmaceuticals key stats
- Compare share trading platforms
- Is GW Pharmaceuticals stock a buy or sell?
- GW Pharmaceuticals performance over time
- Can I short GW Pharmaceuticals shares?
- Are GW Pharmaceuticals shares over-valued?
- GW Pharmaceuticals's financials
- How volatile are GW Pharmaceuticals shares?
- Does GW Pharmaceuticals pay a dividend?
- Other common questions
GW Pharmaceuticals share priceUse our graph to track the performance of GWPH stocks over time.
GW Pharmaceuticals shares at a glance
|Latest market close||USD$100.44|
|52-week range||USD$67.98 - USD$141.98|
|50-day moving average||USD$105.4351|
|200-day moving average||USD$110.9711|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.065|
Standard brokerage - US shares
Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.
- $0 brokerage for US stocks
- Trades starting from $50
- Fractional shares
- Copy top traders
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy GW Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
GW Pharmaceuticals price performance over time
|1 week (2020-09-21)||0.38%|
|1 month (2020-08-28)||-2.46%|
|3 months (2020-06-26)||-16.44%|
|6 months (2020-03-27)||17.13%|
|1 year (2019-09-27)||-13.72%|
|2 years (2018-09-28)||-41.85%|
|3 years (2017-09-28)||-10.54%|
|5 years (2015-09-28)||10.46%|
Is GW Pharmaceuticals under- or over-valued?
Valuing GW Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GW Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GW Pharmaceuticals's P/E ratio
GW Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 91x. In other words, GW Pharmaceuticals shares trade at around 91x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
GW Pharmaceuticals's PEG ratio
GW Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.37. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GW Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
GW Pharmaceuticals financials
|Revenue TTM||US$442 million|
|Gross profit TTM||US$284.1 million|
|Return on assets TTM||-3.94%|
|Return on equity TTM||-7.68%|
|Market capitalisation||US$3.2 billion|
TTM: trailing 12 months
Shorting GW Pharmaceuticals shares
There are currently 4.4 million GW Pharmaceuticals shares held short by investors – that's known as GW Pharmaceuticals's "short interest". This figure is 2.3% down from 4.5 million last month.
There are a few different ways that this level of interest in shorting GW Pharmaceuticals shares can be evaluated.
GW Pharmaceuticals's "short interest ratio" (SIR)
GW Pharmaceuticals's "short interest ratio" (SIR) is the quantity of GW Pharmaceuticals shares currently shorted divided by the average quantity of GW Pharmaceuticals shares traded daily (recently around 435795.3326713). GW Pharmaceuticals's SIR currently stands at 10.07. In other words for every 100,000 GW Pharmaceuticals shares traded daily on the market, roughly 10070 shares are currently held short.
However GW Pharmaceuticals's short interest can also be evaluated against the total number of GW Pharmaceuticals shares, or, against the total number of tradable GW Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GW Pharmaceuticals's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 GW Pharmaceuticals shares in existence, roughly 140 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable GW Pharmaceuticals shares, roughly 0 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against GW Pharmaceuticals.
Find out more about how you can short GW Pharmaceuticals stock.
GW Pharmaceuticals share dividends
We're not expecting GW Pharmaceuticals to pay a dividend over the next 12 months.
GW Pharmaceuticals share price volatility
Over the last 12 months, GW Pharmaceuticals's shares have ranged in value from as little as US$67.98 up to US$141.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GW Pharmaceuticals's is 1.7781. This would suggest that GW Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
GW Pharmaceuticals overview
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Frequently asked questions
Ask an Expert